PaxVax appoints COO Farzan as president; Immunovaccine gets green light for RSV vaccine trial;

> PaxVax has appointed COO Nima Farzan as company president and COO. Release

> Takeda's vaccines president Rajeev Venkayya says his company is evaluating potential candidates in its pipeline that might have an impact on the Ebola virus. Interview

> Health Canada has cleared Immunovaccine to begin a Phase I trial of its RSV vaccine candidate. Release

> Two patients have been on Aduro Biotech's cancer vaccine combo regimen for more than two years and have snown no evidence of cumulative toxicity. Release

Half of girls ages 11-12, the age the CDC recommends, receive the HPV vaccine. Report

And Finally... A new study confirms long-held speculation that anti-vaccine sentiment can concentrate in communities, increasing the risk of outbreaks. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.